Topotecan

• UNSPSC Description:

  Topotecan (SKF 104864A; NSC 609669) is an orally active and potent Topoisomerase I inhibitor. Topotecan induces cell cycle arrest in G0/G1 and S phases and promotes apoptosis. Topotecan shows anticancer activity[1].

• Target Antigen:

  Apoptosis; Autophagy; Topoisomerase

• Type:

  Reference compound

• Related Pathways:

  Apoptosis;Autophagy;Cell Cycle/DNA Damage

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/topotecan.html

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  O=C1[C@](O)(CC)C2=C(CO1)C(N3CC4=CC5=C(CN(C)C)C(O)=CC=C5N=C4C3=C2)=O

• Molecular Weight:

  421.45

• References & Citations:

  [1]Zhang FL, et al. PLoS One. 2013 Nov 26;8(11):e81815.Topoisomerase I inhibitors, Shikonin and Topotecan, inhibit growth and induce apoptosis of glioma cells andglioma stem cells.|[2]Kumar S, et al. Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor. Clin Cancer Res. 2011 Sep 1;17(17):5656-67.Acta Pharmacol Sin. 2021 Jan;42(1):108-114.|bioRxiv. 2023 Apr 14.|Cancer Immunol Res. 2023 May 3;11(5):583-599.|Cancers (Basel). 2022, 14(1), 193.|Cell Commun Signal. 2024 Jun 13;22(1):325.|Cell Death Dis. 2024 Jan 18;15(1):66.|J Biomed Inform. 2023 May 15;104383.|J Exp Clin Cancer Res. 2018 Dec 20;37(1):321. |J Immunol. 2022 Jun 20;ji2100963.|Nat Commun. 2019 Aug 21;10(1):3761.|Pharmaceutics. 2022, 14(12), 2595|Phytochemistry. 2021 Sep 1;191:112910.|Sci Rep. 2019 Oct 22;9(1):15099. |Biochem Pharmacol. 2023 Aug 25;115769.|bioRxiv. 2024 July 07.|Cancer Res. 2023 Nov 21:OF1-OF15.|Cell Rep Methods. 2023 Oct 23;3(10):100599.|Eur J Med Chem. 2024 Dec 5.|FASEB Bioadv. 2020 Mar 7;2(4):254-263.|J Extracell Vesicles. 2022 Apr;11(4):e12206.|J Mol Med (Berl). 2019 Aug;97(8):1183-1193.|J Transl Med. 2024 Aug 14;22(1):766.|J Virol. 2019 May 15;93(11):e02230-18. |NPJ Precis Oncol. 2024 Jun 5;8(1):128.|Pharmacol Res. 2024 May 9:204:107208.|Universitat Autònoma de Barcelona. Biologia Molecular i Biomedicina. 2022 Aug.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  Launched

• CAS Number:

  123948-87-8